VIDEO: SABCS includes ‘exciting’ research in HR-positive breast cancer
In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, discusses some of the highlights in hormone receptor-positive breast cancer presented at this year’s San Antonio Breast Cancer Symposium.
“There’s been a lot of exciting things so far in the hormone receptor-positive breast cancer space,” Shah said.
She mentioned results from multiple presentations involving HR-positive breast cancer, including the PALLAS study examining adjuvant palbociclib (Ibrance, Pfizer) in early hormone receptor positive, HER2-negative breast cancer and findings from the MONALEESA studies examining ribociclib (Kisqali, Novartis) in breast cancer subsets.
Reference:
- Carey L, et al. GS2-00. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
- Gnant M. GS1-07. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
- O’Shaughnessy J. GS2-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about